CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

CDK 4 and 6 Inhibitors: Differences in Target and Dosing Regime

MONARCH-1: Abemaciclib Monotherapy Activity

Side Effects That Require Appropriate Monitoring

CDK 4 and 6 Inhibitors in Patients With Brain Metastases

Concluding Remarks

Concluding Remarks (cont)

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer

Current CDK 4 and 6 Inhibitors for HR-Positive, HER2-Negative Metastatic Breast Cancer

When Do We Use a CDK 4 and 6 Inhibitor?

Subgroup Analyses Across Trials Demonstrates Benefit with CDK 4 and 6 Inhibitors

FALCON Trial: Fulvestrant vs Anastrozole

MONALEESA-2: First-Line Letrozole Plus Ribociclib vs Letrozole Alone

Patients With Poor Prognostic Factors May Benefit From Abemaciclib

MONALEESA 7: Pre- and Peri-Menopausal Patients

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

CDK 4 and 6 Inhibitors for the Treatment of HR-Positive, HER2-Negative Breast Cancer

MONARCH-2: Results

MONARCH-3: Results

MONALEESA 7: Pre- and Peri-Menopausal Patients

CDK 4 and 6 Inhibitors: Consistent Results

Patients With Poor Prognostic Factors May Benefit From Abemaciclib

Concluding Remarks

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

CDK 4 and 6 Inhibitors for the Treatment of HR-Positive, HER2-Negative Breast Cancer

CDK 4 and 6 Inhibitors: Incidence of Neutropenia

Non-Hematological Side Effects Associated With CDK 4 and 6 Therapy

Other Side Effects Associated With CDK 4 and 6 Therapy

Management of Neutropenia

Dose Adjustments for Patients With Non-Hematological Toxicities

Concluding Remarks

Abbreviations

Abbreviations (cont)